Kentaro Inamura1, Mingyang Song1, Seungyoun Jung1, Reiko Nishihara1, Mai Yamauchi1, Paul Lochhead1, Zhi Rong Qian1, Sun A Kim1, Kosuke Mima1, Yasutaka Sukawa1, Atsuhiro Masuda1, Yu Imamura1, Xuehong Zhang1, Michael N Pollak1, Christos S Mantzoros1, Curtis C Harris1, Edward Giovannucci1, Charles S Fuchs1, Eunyoung Cho1, Andrew T Chan1, Kana Wu1, Shuji Ogino1. 1. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (KI, RN, MY, PL, ZRQ, SAK, KM, YS, YI, CSF, SO); Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD (KI, CCH); Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan (KI); Department of Nutrition (MS, RN, EG, KW), Department of Epidemiology (MS, EG, SO), and Department of Biostatistics (RN), Harvard T. H. Chan School of Public Health, Boston, MA; Channing Division of Network Medicine, Department of Medicine (SJ, XZ, EG, CSF, EC, ATC) and Department of Pathology (SO), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA (PL, ATC); Department of Oncology, McGill University, Montreal, Quebec, Canada (MNP); Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (CSM); Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School, Boston, MA (CSM); Department of Dermatology, Warren Alpert Medical School of Brown University, Province, RI (EC).
Abstract
BACKGROUND: Low levels of adiponectin (ADIPOQ; HGNC ID; HGNC:13633), an adipokine, are associated with obesity, adiposity, excess energy balance, and increased risk of colorectal neoplasia. Given the reported association of increased body mass index (BMI) and low-level physical activity with KRAS-mutated colorectal tumor, we hypothesized that low-level plasma adiponectin might be associated with increased risk of KRAS-mutant colorectal carcinoma but not with risk of KRAS wild-type carcinoma. METHODS: We conducted molecular pathological epidemiology research using a nested case-control study design (307 incident rectal and colon cancer case patients and 593 matched control individuals) within prospective cohort studies, the Nurses' Health Study (152 case patients and 297 control individuals, with blood collection in 1989-1990) and the Health Professionals Follow-up Study (155 case patients and 296 control individuals, with blood collection in 1993-1995). Multivariable conditional logistic regression models and two-sided likelihood ratio tests were used to assess etiologic heterogeneity of the associations. RESULTS: The association of low-level plasma adiponectin with colorectal cancer risk statistically significantly differed by KRAS mutation status (P heterogeneity = .004). Low levels of plasma adiponectin were associated with KRAS-mutant colorectal cancer (for the lowest vs highest tertile: multivariable odds ratio [OR] = 2.83, 95% confidence interval [CI] = 1.50 to 5.34, P trend = .002) but not with KRAS wild-type cancer (for the lowest vs highest tertile: multivariable OR = 0.83, 95% CI = 0.49 to 1.43, P trend = .48). In secondary analyses, the association between plasma adiponectin and colorectal cancer did not appreciably differ by BRAF or PIK3CA oncogene mutation status. CONCLUSIONS: Low-level plasma adiponectin is associated with KRAS-mutant colorectal cancer risk but not with KRAS wild-type cancer risk.
BACKGROUND: Low levels of adiponectin (ADIPOQ; HGNC ID; HGNC:13633), an adipokine, are associated with obesity, adiposity, excess energy balance, and increased risk of colorectal neoplasia. Given the reported association of increased body mass index (BMI) and low-level physical activity with KRAS-mutated colorectal tumor, we hypothesized that low-level plasma adiponectin might be associated with increased risk of KRAS-mutant colorectal carcinoma but not with risk of KRAS wild-type carcinoma. METHODS: We conducted molecular pathological epidemiology research using a nested case-control study design (307 incident rectal and colon cancer case patients and 593 matched control individuals) within prospective cohort studies, the Nurses' Health Study (152 case patients and 297 control individuals, with blood collection in 1989-1990) and the Health Professionals Follow-up Study (155 case patients and 296 control individuals, with blood collection in 1993-1995). Multivariable conditional logistic regression models and two-sided likelihood ratio tests were used to assess etiologic heterogeneity of the associations. RESULTS: The association of low-level plasma adiponectin with colorectal cancer risk statistically significantly differed by KRAS mutation status (P heterogeneity = .004). Low levels of plasma adiponectin were associated with KRAS-mutant colorectal cancer (for the lowest vs highest tertile: multivariable odds ratio [OR] = 2.83, 95% confidence interval [CI] = 1.50 to 5.34, P trend = .002) but not with KRAS wild-type cancer (for the lowest vs highest tertile: multivariable OR = 0.83, 95% CI = 0.49 to 1.43, P trend = .48). In secondary analyses, the association between plasma adiponectin and colorectal cancer did not appreciably differ by BRAF or PIK3CA oncogene mutation status. CONCLUSIONS: Low-level plasma adiponectin is associated with KRAS-mutant colorectal cancer risk but not with KRAS wild-type cancer risk.
Authors: Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar Journal: JAMA Date: 2010-10-27 Impact factor: 56.272
Authors: Christophe Rosty; Joanne P Young; Michael D Walsh; Mark Clendenning; Rhiannon J Walters; Sally Pearson; Erika Pavluk; Belinda Nagler; David Pakenas; Jeremy R Jass; Mark A Jenkins; Aung Ko Win; Melissa C Southey; Susan Parry; John L Hopper; Graham G Giles; Elizabeth Williamson; Dallas R English; Daniel D Buchanan Journal: Mod Pathol Date: 2013-01-25 Impact factor: 7.842
Authors: Xiaoyun Liao; Teppei Morikawa; Paul Lochhead; Yu Imamura; Aya Kuchiba; Mai Yamauchi; Katsuhiko Nosho; Zhi Rong Qian; Reiko Nishihara; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino Journal: Clin Cancer Res Date: 2012-02-22 Impact factor: 12.531
Authors: Marlies S Reimers; Eliane C M Zeestraten; Peter J K Kuppen; Gerrit Jan Liefers; Cornelis J H van de Velde Journal: Gastroenterol Rep (Oxf) Date: 2013-08-23
Authors: Fred K Tabung; Stephanie A Smith-Warner; Jorge E Chavarro; Kana Wu; Charles S Fuchs; Frank B Hu; Andrew T Chan; Walter C Willett; Edward L Giovannucci Journal: J Nutr Date: 2016-06-29 Impact factor: 4.798
Authors: Keming Yang; Xin Li; Michele R Forman; Patrick O Monahan; Bret H Graham; Amit Joshi; Mingyang Song; Dong Hang; Shuji Ogino; Edward L Giovannucci; Immaculata De Vivo; Andrew T Chan; Hongmei Nan Journal: Carcinogenesis Date: 2019-12-31 Impact factor: 4.944
Authors: Fred K Tabung; Teresa T Fung; Jorge E Chavarro; Stephanie A Smith-Warner; Walter C Willett; Edward L Giovannucci Journal: Int J Cancer Date: 2016-11-14 Impact factor: 7.396
Authors: Katharina Nimptsch; Mingyang Song; Krasimira Aleksandrova; Michail Katsoulis; Heinz Freisling; Mazda Jenab; Marc J Gunter; Konstantinos K Tsilidis; Elisabete Weiderpass; H Bas Bueno-De-Mesquita; Dawn Q Chong; Majken K Jensen; Chunsen Wu; Kim Overvad; Tilman Kühn; Myrto Barrdahl; Olle Melander; Karin Jirström; Petra H Peeters; Sabina Sieri; Salvatore Panico; Amanda J Cross; Elio Riboli; Bethany Van Guelpen; Robin Myte; José María Huerta; Miguel Rodriguez-Barranco; José Ramón Quirós; Miren Dorronsoro; Anne Tjønneland; Anja Olsen; Ruth Travis; Marie-Christine Boutron-Ruault; Franck Carbonnel; Gianluca Severi; Catalina Bonet; Domenico Palli; Jürgen Janke; Young-Ae Lee; Heiner Boeing; Edward L Giovannucci; Shuji Ogino; Charles S Fuchs; Eric Rimm; Kana Wu; Andrew T Chan; Tobias Pischon Journal: Eur J Epidemiol Date: 2017-05-26 Impact factor: 8.082
Authors: Sophia Harlid; Bethany Van Guelpen; Conghui Qu; Björn Gylling; Elom K Aglago; Efrat L Amitay; Hermann Brenner; Daniel D Buchanan; Peter T Campbell; Yin Cao; Andrew T Chan; Jenny Chang-Claude; David A Drew; Jane C Figueiredo; Amy J French; Steven Gallinger; Marios Giannakis; Graham G Giles; Marc J Gunter; Michael Hoffmeister; Li Hsu; Mark A Jenkins; Yi Lin; Victor Moreno; Neil Murphy; Polly A Newcomb; Christina C Newton; Jonathan A Nowak; Mireia Obón-Santacana; Shuji Ogino; John D Potter; Mingyang Song; Robert S Steinfelder; Wei Sun; Stephen N Thibodeau; Amanda E Toland; Tomotaka Ugai; Caroline Y Um; Michael O Woods; Amanda I Phipps; Tabitha Harrison; Ulrike Peters Journal: Int J Cancer Date: 2022-04-22 Impact factor: 7.316